Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial - Cohen, J A; Coles, A J; Arnold, D L (Lancet, 2012)
, et al; CARE-MS I investigators.